Tirzepatide vs Retatrutide vs Semaglutide: Comparing the New Weight Loss Drugs

Three drugs. Three generations of science. And a flood of headlines that make it hard to tell what’s real from what’s hype.

Semaglutide (Wegovy/Ozempic) kicked off the GLP-1 weight loss era. Tirzepatide (Zepbound/Mounjaro) raised the bar. And now retatrutide - a triple-hormone drug still in clinical trials - is posting weight loss numbers that have the medical world paying attention. In December 2025, the WHO issued its first-ever guideline on GLP-1 medicines for obesity [1], signaling just how central these drugs have become.

If you track calories or practice fasting, understanding these medications matters - not because they replace good habits, but because they reshape the landscape around appetite and weight management.

How They Work - Single, Dual, and Triple Agonism

These three drugs target the same family of gut hormones, but each one casts a wider net.

Semaglutide activates a single receptor: GLP-1. It suppresses appetite, slows gastric emptying, and improves insulin regulation [2]. If you track your intake, you’ll notice the effect quickly - daily calorie totals fall without much effort.

Tirzepatide adds a second receptor: GIP. This dual mechanism is believed to explain why it outperforms semaglutide in head-to-head trials [3].

Retatrutide goes further still, targeting GLP-1, GIP, and glucagon receptors. That glucagon component is the key differentiator - it increases energy expenditure and promotes liver fat burning [4].

Each generation adds a hormonal pathway, and each produces incrementally more weight loss. Whether the tradeoffs are worth it is a different question.

The Numbers - Weight Loss Compared

In the SURMOUNT-5 trial - the only direct head-to-head study between two of these drugs - tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks [3]. A large meta-analysis across over 140,000 patients confirmed tirzepatide consistently produces about 4-5 kg more weight loss [5].

Then there’s retatrutide. In the Phase 3 TRIUMPH-4 trial, the highest dose achieved 28.7% body weight loss - roughly 71 pounds - over 68 weeks [6]. Nearly 60% of participants lost at least a quarter of their body weight.

A caveat: the retatrutide numbers come from a placebo-controlled trial, not a head-to-head comparison against the other two drugs. Cross-trial comparisons are useful directionally, but different patient populations and protocols influence outcomes. For anyone tracking calories, though, the takeaway is the same: these drugs dramatically reduce daily intake through reduced hunger, not willpower.

Safety and Side Effects - What to Expect

All three drugs share a common side effect profile: nausea, diarrhea, constipation, and vomiting. These are worst during the early dose-escalation phase and generally mild to moderate [7]. Most people find they settle down after a few weeks.

Where things diverge is with retatrutide. TRIUMPH-4 flagged a new safety signal - dysesthesia (abnormal tingling or burning) - affecting 20.9% of participants at the highest dose versus less than 1% on placebo [8]. This wasn’t seen in earlier trials, which raised eyebrows among analysts. The events were generally mild, but about 18% of patients on the highest dose stopped treatment due to side effects [6].

All three share class-wide contraindications: personal or family history of medullary thyroid cancer, pregnancy, and severe GI diseases [2].

Beyond the Scale

These drugs deliver more than just weight loss. Retatrutide reduced liver fat by over 80%, with the vast majority of participants reaching normal levels [4]. All three improve cardiovascular markers like blood pressure, cholesterol, and triglycerides. Retatrutide also reduced knee osteoarthritis pain by up to 75.8% [6] - meaningful for people whose joint pain makes exercise difficult.

These benefits compound with habits you’re already building - better liver health, lower blood pressure, and less joint pain all make it easier to stay active.

What Happens When You Stop

This is the section that matters most if you care about long-term results.

After stopping semaglutide, patients regained about 11.6% of lost weight. Tirzepatide users saw around 14% regain [9]. Even participants who maintained a 500-calorie daily deficit and exercised regularly couldn’t fully hold onto their medication-driven losses. This is why the WHO now frames obesity as a chronic condition requiring ongoing management [1].

But here’s the encouraging part: 200-300 minutes per week of moderate exercise, resistance training, and higher protein intake all help protect against regain [9]. These are exactly the kinds of habits that calorie and fasting trackers are already building. The medication gives you a window of reduced appetite - use it to lock in routines that protect you regardless of what happens with your prescription.

What’s Available Now vs. What’s Coming

Semaglutide (Wegovy/Ozempic) has been available since 2021 with the most real-world data. Tirzepatide (Zepbound/Mounjaro) has been available since 2023 and offers stronger efficacy.

Retatrutide is not approved. It’s still in Phase 3 trials, with seven TRIUMPH studies expected to report throughout 2026. Industry analysts estimate FDA approval could come in late 2027 or 2028. Cost remains a major barrier - current GLP-1 medications run $1,000-1,500 per month, and the WHO estimates these therapies will reach fewer than 10% of eligible people globally by 2030 [1].

The Muscle Loss Question

None of these major trials have provided detailed body composition data. The headline numbers don’t distinguish between fat and muscle, and researchers have cautioned that dramatic weight loss could involve “clinically significant declines in muscle and bone mass” [4].

This is where tracking habits become a genuine advantage. Prioritizing protein (at least 1.2 g/kg/day) and strength training 2-3 times per week are the best strategies to protect lean mass during rapid weight loss.

Bottom Line

The hierarchy is straightforward: retatrutide produces the most weight loss, followed by tirzepatide, followed by semaglutide. But more weight loss also means more side effects and - in retatrutide’s case - a drug that isn’t available yet. Semaglutide is the proven option with the longest track record. Tirzepatide offers better results with a similar safety profile. Retatrutide is the most promising drug on the horizon, but it’s still investigational.

No matter which direction the science goes, the people who do best are the ones who use the appetite suppression as a runway to build sustainable habits - tracking what they eat, staying active, and paying attention to nutrition quality, not just the number on the scale. You’re already doing that work, and it counts.

This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication or making significant changes to your diet or exercise routine.

References

1. “WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity.” WHO, 2025.
2. “Glucagon-Like Peptide-1 Receptor Agonists.” StatPearls, 2024.
3. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).” NEJM, 2024.
4. “Retatrutide: A Game Changer in Obesity Pharmacotherapy.” PMC, 2025.
5. “Comparative Efficacy of Tirzepatide vs. Semaglutide: Systematic Review and Meta-Analysis.” PMC, 2025.
6. “Lilly’s Triple Agonist Retatrutide TRIUMPH-4 Phase 3 Results.” Eli Lilly, 2026.
7. “Top GLP-1 Agonists Balance Weight Loss Efficacy, Safety.” AJMC, 2025.
8. “Lilly’s Retatrutide Scores Triple Trial Triumph, But New Safety Signal Emerges.” BioSpace, 2026.
9. “Weight Reduction with GLP-1 Agonists and Paths for Discontinuation.” PMC, 2025.